Skip to main content
Home
Latest news
Browse topics
Lupus Rheumatoid arthritis Spondyloarthropathies COVID-19 Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA Anifrolumab for the treatment of SLE JAK inhibitor safety: Weighing up the data and understanding the risks Rituximab and rheumatology practice in the COVID-19 era Safety snapshot: Upadacitinib in patients with PsA Repurposing rheumatology drugs for COVID-19 Telemedicine in rheumatology: COVID-19 and beyond Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022 EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH
Top

22-07-2017 | Systemic lupus erythematosus | Review | Article

Reproductive Issues in Males with SLE

Journal: Current Treatment Options in Rheumatology

Authors: Omid Zahedi Niaki, MD, Sasha Bernatsky, MD, PhD, Evelyne Vinet, MD, PhD

Publisher: Springer International Publishing

Login to get access

Abstract

Purpose of review Sexual function and fertility are neglected topics in men with systemic lupus erythematosus (SLE) in the literature. This review examines the impact of SLE and its treatment on fertility and erectile function.
Recent findings Systemic illness, such as chronic kidney disease, and drugs used in SLE are associated with male infertility and sexual dysfunction through changes at the level of the hypothalamic-pituitary axis and direct testicular damage. In SLE patients, evidence shows a dose-dependent gonadotoxicity associated with intravenous (IV) cyclophosphamide (CYC). In contrast, recent observational studies evaluating disease-modifying anti-rheumatic drugs, non-steroidal anti-inflammatory drugs, and corticosteroids have found little evidence suggesting a significant impact of paternal exposure on fertility or pregnancy outcomes. In most patients, infertility management is focused on controlling SLE disease activity, minimizing the dose of gonadotoxic medications and cryopreserving sperm prior to treatment with IV CYC.
Summary Reproductive issues are not uncommon in males with SLE. Understanding the impact of disease activity and drug effects on reproductive health may avert irreversible infertility and improve patient quality of life. However, additional studies are required to further explore the impact of SLE and its treatment on male fertility.
Literature
1.
Lu LJ, et al. Review: male systemic lupus erythematosus: a review of sex disparities in this disease. Lupus. 2009;19(2):119–29.CrossRefPubMed
2.
Tan TC, et al. Differences between male and female systemic lupus erythematosus in a multiethnic population. J Rheumatol. 2012;39(4):759.CrossRefPubMedPubMedCentral
3.
Andrade RM, et al. Accelerated damage accrual among men with systemic lupus erythematosus: XLIV. Results from a multiethnic US cohort. Arthritis Rheum. 2007;56(2):622–30.CrossRefPubMed
4.
Murphy G, Isenberg D. Effect of gender on clinical presentation in systemic lupus erythematosus. Rheumatology (Oxford). 2013;52(12):2108–15.CrossRef
5.
Mok CC, Lau CS. Profile of sex hormones in male patients with systemic lupus erythematosus. Lupus. 2000;9(4):252–7.CrossRefPubMed
6.
Athreya BHB. Adenohypophyseal and sex hormones in pediatric rheumatic diseases. J Rheumatol. 20(4):725–30.
7.
Vilarinho STS. Evaluation of the hypothalamic-pituitary-gonadal axis in males with systemic lupus erythematosus. J Rheumatol. 25(6):1097–103.
8.
Soares PMF, et al. Gonad evaluation in male systemic lupus erythematosus. Arthritis & Rheumatism. 2007;56(7):2352–61.CrossRef
9.
Suehiro RM, et al. Testicular Sertoli cell function in male systemic lupus erythematosus. Rheumatology. 2008;47(11):1692–7.CrossRefPubMed
10.
D'Cruz OJ, Haas GG, Reichlin M. Autoantibodies to decondensed sperm nuclear deoxyribonucleic acid in patients with antisperm antibodies and systemic lupus erythematosus detected by immunofluorescence flow cytometry. Fertil Steril. 1994;62(4):834–44.CrossRefPubMed
11.
Shiraishi Y, et al. Incidence of antisperm antibodies in males with systemic autoimmune diseases. Am J Reprod Immunol. 2009;61(3):183–9.CrossRefPubMed
12.
Rovin, B.H. and I.E. Stillman, Chapter 42 - Kidney A2- Lahita, Robert G. 2011, Academic Press: San Diego. p. 769–814.
13.
de Carvalho JF, et al. Male gender results in more severe lupus nephritis. Rheumatol Int. 2010;30(10):1311–5.CrossRefPubMed
14.
Hanly JG, et al. The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology (Oxford). 2016;55(2):252–62.CrossRef
15.
Palmer BF, Clegg DJ. Gonadal dysfunction in chronic kidney disease. 2017;18(1):117–30.
16.
Handelsman DJ. Hypothalamic-pituitary gonadal dysfunction in renal failure, dialysis and renal transplantation. Endocr Rev. 1985;6(2):151–82.CrossRefPubMed
17.
Rathi M, Ramachandran R. Sexual and gonadal dysfunction in chronic kidney disease: pathophysiology. Indian Journal of Endocrinology and Metabolism. 2012;16(2):214–9.CrossRefPubMedPubMedCentral
18.
Rabelo-Júnior CN, et al. Penile alterations with severe sperm abnormalities in antiphospholipid syndrome associated with systemic lupus erythematosus. Clin Rheumatol. 2013;32(1):109–13.CrossRefPubMed
19.
Dillon SP, et al. Sex chromosome aneuploides among men with systemic lupus erythematosus. J Autoimmun. 2012;38(2–3):J129–34.CrossRefPubMed
20.
Maiburg M, Repping S, Giltay J. The genetic origin of Klinefelter syndrome and its effect on spermatogenesis. Fertil Steril. 2012;98(2):253–60.CrossRefPubMed
21.
Rivkees SA, Crawford JD. THe relationship of gonadal activity and chemotherapy-induced gonadal damage. JAMA. 1988;259(14):2123–5.CrossRefPubMed
22.
Buchanan JD, Fairley KF, Barrie JU. Return of spermatogenesis after stopping cyclophosphamide after therapy. Lancet. 1975;306(7926):156–7. Originally published as Volume 1, Issue 7926CrossRef
23.
• Houssiau FA, et al. Immunosuppressive therapy in lupus nephritis: The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 2002;46(8):2121–31. An important trial that established that a low-dose and therefore less gonadotoxic cyclophosphamide regimen appears as effective as higher dose regimens in the treatment of lupus nephritis.CrossRefPubMed
24.
The, A.T.G, et al. Treatment of lupus nephritis with abatacept: the abatacept and cyclophosphamide combination efficacy and safety study. Arthritis & rheumatology (Hoboken, NJ). 2014;66(11):3096–104.
25.
Gajjar R, et al. Fertility preservation in patients receiving cyclophosphamide therapy for renal disease. Pediatr Nephrol. 2015;30(7):1099–106.CrossRefPubMed
26.
• Lee SJ, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol. 2006;24(18):2917–31. A review detailing the feasibility of future fertility restoration through autologous transplantation of cryopreserved spermatogonial stem cells (SSCs).CrossRefPubMed
27.
Mersereau J, Dooley MA. Gonadal failure with cyclophosphamide therapy for lupus nephritis: advances in fertility preservation. Rheum Dis Clin N Am. 2010;36(1):99–108. viiiCrossRef
28.
Ginsberg JP, et al. An experimental protocol for fertility preservation in prepubertal boys recently diagnosed with cancer: a report of acceptability and safety. Human Reproduction (Oxford, England). 2010;25(1):37–41.CrossRef
29.
Onofre J, et al. Cryopreservation of testicular tissue or testicular cell suspensions: a pivotal step in fertility preservation. Hum Reprod Update. 2016;22(6):744–61.CrossRefPubMedPubMedCentral
30.
Russell JA, Powles RL, Oliver RT. Conception and congenital abnormalities after chemotherapy of acute myelogenous leukaemia in two men. BMJ. 1976;1(6024):1508.CrossRefPubMedPubMedCentral
31.
Janssen NM, Genta MS. THe effects of immunosuppressive and anti-inflammatory medications on fertility, pregnancy, and lactation. Arch Intern Med. 2000;160(5):610–9.CrossRefPubMed
32.
Østensen M, et al. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Research & Therapy. 2006;8(3):209.CrossRef
33.
Hinkes E, Plotkin D. Reversible drug-induced sterility in a patient with acute leukemia. JAMA. 1973;223(13):1490–1.CrossRefPubMed
34.
Sussman A, Leonard JM. Psoriasis, methotrexate, and oligospermia. Arch Dermatol. 1980;116(2):215–7.CrossRefPubMed
35.
El-Beheiry A, et al. Methotrexate and fertility in men. Arch Androl. 1979;3(2):177–9.CrossRefPubMed
36.
Silva CA, Bonfa E, ØStensen M. Maintenance of fertility in patients with rheumatic diseases needing antiinflammatory and immunosuppressive drugs. Arthritis Care & Research. 2010;62(12):1682–90.CrossRef
37.
Aguirre MA, et al. Gynecomastia and sexual impotence associated with methotrexate treatment. J Rheumatol. 2002;29(8):1793–4.PubMed
38.
Wylie G, Evans CD, Gupta G. Reduced libido and erectile dysfunction: rarely reported side-effects of methotrexate. Clin Exp Dermatol. 2009;34(7):e234.CrossRefPubMed
39.
Weber-Schoendorfer C, et al. No evidence for an increased risk of adverse pregnancy outcome after paternal low-dose methotrexate: an observational cohort study. Rheumatology. 2014;53(4):757–63.CrossRefPubMed
40.
• Wallenius M, et al. Brief report: no excess risks in offspring with paternal preconception exposure to disease-modifying antirheumatic drugs. Arthritis & Rheumatology. 2015;67(1):296–301. A Norwegian registry study revealing no impact of paternal exposure to DMARDs (mainly MTX) on pregnancy and fetal outcomes.CrossRef
41.
Dejaco C, et al. Azathioprine treatment and male fertility in inflammatory bowel disease. Gastroenterology. 2001;121(5):1048–53.CrossRefPubMed
42.
Xu L, et al. The influence of immunosuppressants on the fertility of males who undergo renal transplantation and on the immune function of their offspring. Transpl Immunol. 2009;22(1–2):28–31.CrossRefPubMed
43.
Nørgård B, et al. The risk of congenital abnormalities in children fathered by men treated with azathioprine or mercaptopurine before conception. Aliment Pharmacol Ther. 2004;19(6):679–85.CrossRefPubMed
44.
45.
Myfortic® (Mycophenolic acid enteric-coated tablets 180 mg, 360 mg (as mycophenolate sodium)) [product monograph on the Internet]. Dorval (QC): Novartis Pharmaceuticals Canada Inc. 2005 [revised 2016]. Available from: https://​www.​ask.​novartispharma.​ca/​download.​htm?​res=​myfortic_​scrip_​e.​pdf&​resTitleId=​805
46.
Jones A, et al. Outcomes of pregnancies fathered by solid-organ transplant recipients exposed to mycophenolic acid products. Prog Transplant. 2013;23(2):153–7.CrossRefPubMed
47.
Morken NH, et al. Obstetric and neonatal outcome of pregnancies fathered by males on immunosuppression after solid organ transplantation. Am J Transplant. 2015;15(6):1666–73.CrossRefPubMed
48.
Kamischke A, et al. Testosterone levels in men with chronic obstructive pulmonary disease with or without glucocorticoid therapy. Eur Respir J. 1998;11(1):41.CrossRefPubMed
49.
Odell WD. Testosterone treatment of men treated with glucocorticoids. Arch Intern Med. 1996;156(11):1133–4.CrossRefPubMed
50.
Mac AM, White RH, Chipps BE. Reduction of serum testosterone levels during chronic glucocorticoid therapy. Ann Intern Med. 1986;104(5):648–51.CrossRef
51.
Martini AC, et al. Analysis of semen from patients chronically treated with low or moderate doses of aspirin-like drugs. Fertil Steril. 2003;80(1):221–2.CrossRefPubMed
52.
Gleason JM, et al. Regular nonsteroidal anti-inflammatory drug use and erectile dysfunction. J Urol. 2011;185(4):1388–93.CrossRefPubMed
53.
Shiri R, et al. Effect of nonsteroidal anti-inflammatory drug use on the incidence of erectile dysfunction. J Urol. 2006;175(5):1812–6.CrossRefPubMed
Image Credits